BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.07), $0.15 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $391.7 million versus the consensus estimate of $367.09 million.

GUIDANCE:

BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of $1.51 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.